Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2024-02-27 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PRTC to Present at Cowen and Leerink Conferences
Regulatory Filings Classification · 99% confidence The document is a press release distributed via RNS (Regulatory News Service), indicated by the 'RNS Number' and the footer information. The content announces that members of the management team will participate in two upcoming investor conferences (TD Cowen and Leerink Partners) and provides details about the dates and presenters. This type of announcement, which informs the market about management's schedule for engaging with investors, is best classified as an Investor Presentation (IP) related activity or, more broadly, a general regulatory announcement. Since it is not the presentation itself, but an announcement *about* presentations/participation, and it is distributed through the RNS system, it fits the criteria for a general regulatory announcement or a specific announcement related to investor engagement. Given the options, 'Investor Presentation' (IP) covers the subject matter (presenting to investors), but 'Report Publication Announcement' (RPA) or 'Regulatory Filings' (RNS) are also possibilities if it were just a notice of a report. Since this is an announcement of management participation in external investor events, and it is distributed via RNS, it is a standard regulatory disclosure. It is not a formal report (10-K, IR, ER, etc.). It is an announcement about future investor engagement. This is often categorized under general investor relations disclosures. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a standard RNS announcement that doesn't fit a more specific category like ER or DIV, although 'IP' relates to the topic. However, since it is a notice *about* participation, and not the presentation material itself, RNS is safer, or RPA if we interpret it as announcing future investor-facing material. Since the core content is announcing participation in investor conferences, which is a form of investor communication, and it is distributed via RNS, I will classify it as RNS as the general regulatory disclosure channel used, as it is not a specific report type.
2024-02-27 English
PRTC: Akili Positive Ph3 & Japan PMDA Submission
Regulatory Filings Classification · 100% confidence The document begins with an RNS Number and a date, indicating a regulatory announcement. The content is a press release from PureTech Health plc, relaying an announcement from its Founded Entity, Akili, regarding the submission for marketing approval in Japan based on positive Phase 3 clinical trial results. This type of announcement, detailing clinical trial outcomes and regulatory submissions, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific corporate event announcement that doesn't fit other categories. Since it is a press release announcing a significant corporate/clinical development (submission for marketing approval), and it is distributed via RNS, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific dividend/capital change notice. It is a general corporate update distributed through the regulatory news service.
2024-02-27 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: "PureTech Health PLC ... Transaction in Own Shares". It details the purchase of ordinary shares by the company through a broker, completing a previously announced Share Buyback Programme. The content focuses entirely on the volume, price, and total number of shares repurchased, which directly corresponds to the definition of 'Transaction in Own Shares'. This maps precisely to the filing type code POS (Transaction in Own Shares). The presence of the RNS Number and the footer referencing RNS/LSE confirms it is a regulatory disclosure, but the specific content dictates the most accurate classification.
2024-02-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC dated February 7, 2024. The title explicitly states 'Transaction in Own Shares' and the content details the purchase of ordinary shares as part of a 'Share Buyback Programme'. This directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category. This matches Filing Definition 29: Transaction in Own Shares (Code: POS).
2024-02-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its subject matter in the title section: "Transaction in Own Shares". It details the purchase of ordinary shares by PureTech Health PLC as part of its Share Buyback Programme, providing specific dates, volumes, and prices. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the footer referencing RNS/LSE confirms it is a regulatory disclosure, but the content is highly specific to share repurchases.
2024-02-06 English
6-K
Transaction in Own Shares Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, PureTech Health plc, reporting on its share repurchase program activity during January 2024. It details daily purchases of the company's own shares under the program, including volumes and prices, and references regulatory compliance with UK and EU rules. The content focuses on the company's transactions in its own shares, specifically repurchases and treasury holdings. There is no financial statement or earnings data, no management discussion or annual report content, and no mention of voting results or legal proceedings. The document is not a report publication announcement but a detailed disclosure of share repurchase transactions. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2024-02-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.